Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2000 Nov;59(Suppl 1):i41–i43. doi: 10.1136/ard.59.suppl_1.i41

Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update

M Davis, U Feige, A Bendele, S Martin, C Edwards
PMCID: PMC1766629  PMID: 11053086

Full Text

The Full Text of this article is available as a PDF (98.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bendele A. M., McComb J., Gould T., Frazier J., Chlipala E. S., Seely J., Kieft G., Wolf J., Edwards C. K., 3rd Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats. Inflamm Res. 1999 Aug;48(8):453–460. doi: 10.1007/s000110050486. [DOI] [PubMed] [Google Scholar]
  2. Bendele A. M., McComb J., Gould T., Frazier J., Chlipala E., Seely J., Kieft G., Edwards C. K., 3rd Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats. Clin Exp Rheumatol. 1999 Sep-Oct;17(5):553–560. [PubMed] [Google Scholar]
  3. Edwards C. K., 3rd PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I73–I81. doi: 10.1136/ard.58.2008.i73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Goker B., Block J. A. Spinal epidural hematoma complicating active systemic lupus erythematosus. Arthritis Rheum. 1999 Mar;42(3):577–578. doi: 10.1002/1529-0131(199904)42:3<577::AID-ANR25>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  5. Kuiper S., Joosten L. A., Bendele A. M., Edwards C. K., 3rd, Arntz O. J., Helsen M. M., Van de Loo F. A., Van den Berg W. B. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine. 1998 Sep;10(9):690–702. doi: 10.1006/cyto.1998.0372. [DOI] [PubMed] [Google Scholar]
  6. McComb J., Gould T., Chlipala E., Sennelo G., Frazier J., Kieft G., Seely J., Edwards C. K., 3rd, Bendele A. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy. J Rheumatol. 1999 Jun;26(6):1347–1351. [PubMed] [Google Scholar]
  7. Moreland L. W., McCabe D. P., Caldwell J. R., Sack M., Weisman M., Henry G., Seely J. E., Martin S. W., Yee C. L., Bendele A. M. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J Rheumatol. 2000 Mar;27(3):601–609. [PubMed] [Google Scholar]
  8. Solorzano C. C., Kaibara A., Hess P. J., Edwards P. D., Ksontini R., Abouhamze A., McDaniel S., Frazier J., Trujillo D., Kieft G. Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. J Appl Physiol (1985) 1998 Apr;84(4):1119–1130. doi: 10.1152/jappl.1998.84.4.1119. [DOI] [PubMed] [Google Scholar]
  9. Su X., Zhou T., Yang P., Edwards C. K., 3rd, Mountz J. D. Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor. Arthritis Rheum. 1998 Jan;41(1):139–149. doi: 10.1002/1529-0131(199801)41:1<139::AID-ART17>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  10. Torelli G. F., Meguid M. M., Moldawer L. L., Edwards C. K., 3rd, Kim H. J., Carter J. L., Laviano A., Rossi Fanelli F. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol. 1999 Sep;277(3 Pt 2):R850–R855. doi: 10.1152/ajpregu.1999.277.3.R850. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES